Citizens Maintains Market Outperform on Taysha Gene Therapies, Raises Price Target to $8
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Citizens analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and raises the price target from $6 to $8.
Citizens analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and raises the price target from $6 to $8.